Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Accelerate Diagnostics, Inc. (AXDX) specializes in developing innovative diagnostic solutions for infectious diseases, particularly in the area of antibiotic resistance. The company's flagship product, the Accelerate Pheno system, is designed to provide rapid and accurate identification of pathogens and their antibiotic susceptibility, which is critical in hospital settings across the U.S. and Europe.
AXDX generates revenue primarily through the sale of its diagnostic systems and related consumables. The company has a competitive advantage due to its proprietary technology that significantly reduces the time to diagnose infections compared to traditional methods, thus enhancing clinical outcomes and reducing hospital costs.
Adoption rates of the Accelerate Pheno system in hospitals, particularly in the U.S. and Europe
Regulatory approvals for new diagnostic tests
Partnerships or collaborations with larger healthcare providers
Trends in antibiotic resistance and hospital-acquired infections
Technological disruption from rapid advancements in diagnostic technologies
Regulatory changes that could impact the approval process for new products
Emerging competitors with similar or superior diagnostic technologies
Price competition from established players in the diagnostic market
Negative operating cash flow and high operating losses raise concerns about liquidity
Potential dilution of equity if additional financing is required
moderate - The demand for diagnostic devices is somewhat insulated from economic cycles, but hospital budgets can be affected by broader economic conditions.
Interest rates impact AXDX primarily through the cost of capital for financing operations and growth initiatives, as well as affecting hospital capital expenditures.
minimal - The company has a negative debt/equity ratio, indicating it is not heavily reliant on debt financing.
growth - Investors looking for potential high-growth opportunities in the healthcare sector may find AXDX appealing due to its innovative technology.
high - The stock has shown significant volatility, particularly with a recent 97% decline over the past year.
